Biologicals

Influenza

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines containing the pandemic influenza A H1N1 (2009) virus: Update

H1N1 specific-update of TRS 941, Annex 5

Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Recommendations for the production and control of influenza vaccine (inactivated)

WHO Technical Report Series, No. 927, 2005, Annex 3

Influenza vaccine, live

Title: Requirements for Influenza Vaccine (Live); Adopted 1978, TRS No 638, Annex 3

UPCOMING EVENTS

WHO Implementation Workshop: Characterization of cell banks for the production of biologicals, 27-29 May 2013 and WHO Informal Consultation on regulatory risk assessment in the case of adventitious agent finding in a marketed vaccine, 30-31 May 2013, Beijing, Republic of China

WHO Informal Consultation on the Scientific and Regulatory Considerations on the Stability Evaluation of Vaccines under a Controlled Temperature Chain, Langen, Germany, 4-6 June 2013

Expert Committee on Biological Standardization, Geneva, Switzerland, 21-25 October 2013

CONTACTS

Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971